Umoja Biopharma and TreeFrog Therapeutics Announce Collaboration to Address Current Challenges Facing Ex Vivo Allogeneic Therapies in Immuno-Oncology

TFT Bioreactor image for PR

Mass-production of human induced pluripotent stem cells in a 10L bioreactor using TreeFrog Therapeutics’ C-Stem™ technology. Photo credits: TreeFrog Therapeutics

Format

JPEG

Source

Umoja Biopharma, Inc.

Downloads

About Us

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases, financial disclosures and multimedia content to media, investors, and consumers worldwide.

Global News
Newswire Distribution Network & Management

© 2025 Digital Media Innovations, LLC. All rights reserved.